Global Innovative Platforms Inc. (GIPL): auditor change — Inks diagnostic supply deal with animal health co; switches auditor to CNGSN

Global Innovative Platforms Inc.

Agreement to supply VOCAM Plus units and support for evaluation of canine heartworm detection using breathomics.
Dismissed M.S. Madhava Rao as independent auditor effective Nov 3, 2025; no disagreements or adverse opinions.
Appointed CNGSN & Associates LLP as independent auditor for fiscal year ending Sep 30, 2025.

item 1.01 item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Global Innovative Platforms Inc. dismissed M. S. Madhava Rao, Chartered Accountant as its auditor.

Action: dismissal
Auditor: M. S. Madhava Rao, Chartered Accountant

Exact text from the filing

ccountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On November 3, 2025, the Board of Directors (the “Board”) of Global Innovative Platforms, Inc. (the “Company”) dismissed M. S. Madhava Rao, Chartered Accountant (“MSMR”) as the Company’s independent registered public accounting firm, effective

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Global Innovative Platforms Inc. engaged CNGSN & Associates LLP as its auditor.

Action: engagement
Auditor: CNGSN & Associates LLP

Exact text from the filing

ppointment of New Independent Registered Public Accounting Firm On November 3, 2025, the Board approved the engagement of CNGSN & Associates LLP (“CNGSN”) as the Company’s independent registered

View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

Global Innovative Platforms Inc. filing history →

Source: SEC EDGAR

accession 0001731122-25-001501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.